1. Home
  2. REBN vs APRE Comparison

REBN vs APRE Comparison

Compare REBN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reborn Coffee Inc.

REBN

Reborn Coffee Inc.

HOLD

Current Price

$1.26

Market Cap

11.5M

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.84

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REBN
APRE
Founded
2015
2006
Country
United States
United States
Employees
N/A
8
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
10.8M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
REBN
APRE
Price
$1.26
$0.84
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
51.2K
426.7K
Earning Date
04-22-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
$8,094,628.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
36.54
N/A
52 Week Low
$0.91
$0.55
52 Week High
$2.95
$1.69

Technical Indicators

Market Signals
Indicator
REBN
APRE
Relative Strength Index (RSI) 47.39 59.45
Support Level $1.20 $0.74
Resistance Level $2.02 $1.00
Average True Range (ATR) 0.12 0.09
MACD -0.00 0.03
Stochastic Oscillator 31.71 38.70

Price Performance

Historical Comparison
REBN
APRE

About REBN Reborn Coffee Inc.

Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: